Cancer Immunotherapy: Molecular Mechanisms and Novel Potential Targets
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 167
Special Issue Editors
Interests: NK cells; PD-1; inhibitory receptors; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Interests: cancer; immunotherapy; innate immunity; macrophages; innate receptors
Interests: innate lymphoid cells; NK cells; glucocorticoids; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
How the immune system reacts to the onset and progression of a tumor and how tumor cells and the microenvironment shape the immune responses to grow is crucial for understanding the mechanisms underlying the success or the failure of cancer immunotherapies. In recent decades scientists have made significant progress in deciphering the molecular mechanisms involved in cancer immune surveillance and immune escape, helping to develop novel and more effective immunotherapies, including oncolytic virus therapies, cytokines therapies, cancer vaccines, immune checkpoint inhibitors and adoptive cell transfer. This Special Issue encourages authors to present recent progress in the following areas:
- Discerning undefined interactions between immune cells and tumor cells or stroma (cell–cell inhibition, ECM, CAFs, distal stroma and metastases)
- Discovering novel putative targets (i.e., neo-antigens, cytokines and receptors) to develop more specific and successful therapies,
- Eliciting the different genetic (i.e., HLA, non-coding RNA) and environmental (i.e., microbiome, virus infections, co-morbidity) contexts that may affect the outcome of cancer immunotherapies.
In this Special Issue, original research articles and reviews are welcome.
Dr. Francesca Romana Mariotti
Dr. Martina Molgora
Dr. Linda Quatrini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- innate immunity
- adaptive immunity
- cancer vaccines
- immune checkpoint therapy
- adoptive cell transfer
- cytokines
